Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

FHS
April 5, 2024
7:54 pm

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.

Is there an association between diabetes and breast cancer risk?

The relationship between diabetes and the risk of breast cancer.

July 6, 2023

Bernie Sanders targets ‘outrageously high price’ of Ozempic

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Here in

April 25, 2024

Researchers receive DoD grant to target chemotherapy resistance in pancreatic cancer

Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have been awarded a grant from the U.S. Department of

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.